Über Apac Biotech Pvt. Ltd.
Apac Biotech was built on the belief that our immune system is powerful enough to fight cancer from within and now with Apac’s personalised therapies we plan turn the tables on cancer and fight with the cancer patients.
Our flagship product APCEDEN® was the first Indian FDA approved immunotherapy product for the treatment of cancer. Today, our versatile research team of scientists and doctors are going deeper into creating unmatched personalised therapeutics to enhance the immune system further
Mission
Make APCEDEN® personalised immunotherapy available to patient’s in India and around the world
Enhancing the technology further to explore the uses of personalised immunotherapy in other cancer treatments.
Beschreibung
team of APAC Biotech to dig deep in search of new therapeutic options such as adoptive immunotherapy. This new class of cancer treatment works around harnessing the innate powers of the immune system to fight cancer because of its unique properties.
For the very first time in India, people diagnosed with advanced-stage cancer are expected to live longer. And the reason is a revolutionary study conducted by APAC Biotech, under the brand name APCEDENTM, on Dendritic Cell Therapy. APAC Biotech team’s novel therapy inspiration comes from two breakthroughs, Prof Ralph Steinmann’s discovery of the role of Dendritic cells for adoptive immunity in 1970’s and the identification of human cancer antigens.
An open-label, multi-center, non-randomized, single arm study was conducted by first-of-its-kind Indian Biotechnology company, APAC Biotech, to evaluate the safety and efficacy of APCEDEN [Personalized Dendritic Cell (DC) immunotherapy] in patients with refractory solid malignancies, on symptomatic treatment.The development of this cutting-edge formulation is handled by a highly qualified in-house team of scientists, lab technicians &doctors and a state of art infrastructure & technology.
Commercially licensed by Indian FDA (CDSCO- Central Drug Standard Control Organisation), APCEDEN® a Dendritic cell-based autologous Immuno-oncology product to treat advanced refractory cancers namely Prostrate, Ovarian, Colo-rectal, and Non-Small Cell Lung Carcinoma etc. Clinical trials were conducted at renowned Hospitals like Narayan Hridalaya (Bangalore), Sir Gangaram Hospital (Delhi), Indo American Cancer Inst. (Hyderabad), VS Hospital (Chennai), Ruby Hall hospital (Pune) and BIBI Hospital, Hyderabad. These trials were designed to understand the potential benefits and risk of the fourth modality, i.e., APCEDEN [Dendritic Cell (DC) immunotherapy].
Auszeichnungen
APAC is conferred with the Excellence award for DC clinical trial at UAE Cancer Congress at Dubai.
APAC Biotech becomes the first indian Biotechnology Company to receive PMS (post marketing study) approval for its dendritic cell based immunotherapy (APCEDEN®) for four indications, ovarian cancer ,lung cancer ,colon cancer and prostate cancer.
Recevied NOC from the DCGI for APCEDEN® protocol.
